Ayana Pharma

Executive Summary

Ayana Pharma is a preclinical-stage private biotechnology company headquartered in Jerusalem, Israel, founded in 2020. The company focuses on developing novel small molecule therapies for inflammatory and fibrotic diseases, addressing significant unmet medical needs in areas such as idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and systemic sclerosis. By leveraging deep expertise in immunology and fibrosis biology, Ayana aims to discover and advance first-in-class or best-in-class oral small molecules that modulate key disease pathways. Although the company is still in the early preclinical phase, its research is positioned to target validated mechanisms with high translational potential. As a private entity with limited publicly available data, Ayana's progress depends on successful lead optimization and IND-enabling studies. The company operates in a competitive landscape but benefits from a strong scientific foundation and strategic location within Israel's vibrant biotech ecosystem. Key risks include early-stage attrition, funding requirements, and the long timeline to clinical development. Nonetheless, the persistent demand for safer, more effective treatments in inflammatory and fibrotic diseases provides a substantial opportunity if Ayana's candidates demonstrate preclinical promise.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate Selection70% success
• Q1 2027Initiation of IND-Enabling Studies50% success
• Q2 2027Presentation of Preclinical Proof-of-Concept Data at Conference60% success